Anticancer research · 2026
Neoadjuvant Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score-matched Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kishi Takashi, Nakamura Kosuke, Tanaka Takayuki, Ishitobi Kazunari, Kaji Shunsuke, Taniura Takahito, Matsubara Takeshi, Yamamoto Tetsu, Hidaka Masaaki
Аннотация
BACKGROUND/AIM: Neoadjuvant chemotherapy with gemcitabine plus S-1 (NAC-GS) is recommended for patients with resectable pancreatic ductal adenocarcinoma (PDAC) in Japan. However, its real-world feasibility, the impact of treatment-related toxicity, and the influence of relative dose intensity (RDI) on outcomes remain unclear. This study evaluated the safety and efficacy of NAC-GS for resectable PDAC.
PATIENTS AND METHODS: We retrospectively reviewed 117 patients with resectable PDAC who underwent treatment between January 2017 and December 2024. Outcomes were compared between patients treated with NAC-GS and those who underwent upfront surgery (UFS). Propensity score matching was performed among patients who underwent curative resection to adjust for baseline characteristics. Recurrence-free survival (RFS), overall survival (OS), recurrence patterns, adverse events, and the association between RDI and outcomes were analyzed.
RESULTS: The study included 46 patients in the NAC-GS group and 71 in the UFS group. Resection rates did not differ significantly between the groups. Although grade ≥3 adverse events occurred frequently in the NAC-GS group, no patient became ineligible for surgery because of treatment-related toxicity. After propensity score matching, 32 pairs were analyzed. The NAC-GS group had significantly longer RFS and OS than the UFS group. The 5-year RFS rates were 57.2% and 26.0%, respectively, and the 5-year OS rates were 60.2% and 37.2%, respectively. NAC-GS was also associated with a lower early recurrence rate. In the NAC-GS group, an RDI <70% tended to be associated with poorer survival.
CONCLUSION: NAC-GS was feasible and was associated with improved long-term outcomes and reduced early recurrence in patients with resectable PDAC. Maintaining adequate RDI may be important for maximizing its therapeutic benefit.
PATIENTS AND METHODS: We retrospectively reviewed 117 patients with resectable PDAC who underwent treatment between January 2017 and December 2024. Outcomes were compared between patients treated with NAC-GS and those who underwent upfront surgery (UFS). Propensity score matching was performed among patients who underwent curative resection to adjust for baseline characteristics. Recurrence-free survival (RFS), overall survival (OS), recurrence patterns, adverse events, and the association between RDI and outcomes were analyzed.
RESULTS: The study included 46 patients in the NAC-GS group and 71 in the UFS group. Resection rates did not differ significantly between the groups. Although grade ≥3 adverse events occurred frequently in the NAC-GS group, no patient became ineligible for surgery because of treatment-related toxicity. After propensity score matching, 32 pairs were analyzed. The NAC-GS group had significantly longer RFS and OS than the UFS group. The 5-year RFS rates were 57.2% and 26.0%, respectively, and the 5-year OS rates were 60.2% and 37.2%, respectively. NAC-GS was also associated with a lower early recurrence rate. In the NAC-GS group, an RDI <70% tended to be associated with poorer survival.
CONCLUSION: NAC-GS was feasible and was associated with improved long-term outcomes and reduced early recurrence in patients with resectable PDAC. Maintaining adequate RDI may be important for maximizing its therapeutic benefit.